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PROPENSITY SCORE METHODS: A SIMULATION AND CASE STUDY 
INVOLVING BREAST CANCER PATIENTS 
John A. Craycroft 
April 12, 2016 
Observational data presents unique challenges for analysis that are not encountered with 
experimental data resulting from carefully designed randomized controlled trials.  
Selection bias and unbalanced treatment assignments can obscure estimations of 
treatment effects, making the process of causal inference from observational data highly 
problematic.  In 1983, Paul Rosenbaum and Donald Rubin formalized an approach for 
analyzing observational data that adjusts treatment effect estimates for the set of non-
treatment variables that are measured at baseline.  The propensity score is the conditional 
probability of assignment to a treatment group given the covariates.  Using this score, one 
may balance the covariates across treatment groups and obtain unbiased estimates of 
treatment effects.  This paper has three objectives:  to explain propensity scores, their 
assumptions, and their applications; to illustrate their use and several considerations 
underlying various propensity score methods, by using simulation studies; and to use 
propensity score methods to estimate average treatment effect between two types of 
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Why do we engage in scientific research?  Quite simply, to gain knowledge about 
our world.  Rarely, however, is knowledge sought as nothing more than a snapshot of 
current conditions; rather, we want to understand how conditions change over time.  In 
particular, we want to know what causes those changes, and how causes and effects relate 
to each other. We want to know how things work.  It is probably only a slight 
oversimplification to say that scientific research is, fundamentally, intended to identify 
and describe “cause-and-effect” relationships in our world. 
 For our beliefs derived from scientific research to be true and justified – and thus 
constitute real knowledge – we must have sound logical reasoning underlying the 
inferential process by which we draw general conclusions from empirical data.  One 
aspect of this logical reasoning is that different types of data support different levels of 
causal inference.  Experimental data from a randomized controlled trial may be 
considered the “gold standard” for empirical data that enables justified causal inferences, 
but there exist significant limitations with obtaining and using that type of data.  In this 
paper we are concerned with propensity score methodologies, a set of statistical 
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techniques that aid in the process of gleaning accurate causal inferences from 
observational data.  We will explain what propensity scores are, explore assumptions 
underlying these methodologies, and demonstrate their application on both real world and 
simulated data. 
The structure of the paper will be as follows:  in this Introduction, we will 
describe the potential outcomes framework in which most empirical scientific research is 
conducted; describe two types of treatment effects, and explain how different types of 
covariates relate to treatments and responses.  We will also explain the two main types of 
empirical data and the implications of each for scientific research.  This, finally, will 
motivate the definition of the propensity score. 
In the Methods section, we will present a more thorough exposition of propensity 
scores.  We will define them formally in mathematical notation, explore their various 
properties, and the properties of effect estimates stemming from their use.  We will also 
explain assumptions underlying the propensity score approach, discuss various 
considerations for estimating these scores, and explain several application methods that 
are commonly used after the scores are estimated. 
The third section of this paper will describe the simulation study, while the fourth 
section will describe the case study.  In these sections, we will describe the specific 
objectives of the studies, detail the characteristics of the data sets involved, explain how 
the propensity score methodologies were applied, and present the results.  The final 
section in the body of the paper will provide discussion about those results, as well as 
what conclusions we may make regarding propensity score analysis in general. 
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The Appendix of this paper provides additional tables and charts related to the 
simulation and the case study analysis that were deemed noncritical for inclusion in the 
body of the paper, but useful nevertheless for the reader who may want even more details 
regarding the simulation and/or the case study analysis.  Also in the Appendix, we 
present a highly summarized sketch of important developments in the philosophy of 
knowledge (epistemology); here, within the context of scientific research as a motivating 
paradigm, we highlight key concepts related to logical reasoning and causal inference and 
explain how these lead us to the need for the concept of propensity scores.  
1.2 The potential outcomes framework. 
Nearly all scientific research, at some level, explicitly or implicitly, makes 
assumptions that rely on the notions of counterfactuals.  Counterfactuals are statements 
that invert statements about current or past conditions.  In statistics, this use has been 
formalized in what has been termed the “potential outcomes framework.”  The idea of the 
“potential outcomes framework” is that for any unit in the population, there are two1 
potential outcomes: one outcome if the unit is exposed to the treatment of interest, and 
one outcome if the unit is not exposed to the treatment.  If we let Y be an indicator of the 
outcome of interest (with a value of 1 indicating that the unit had the specific outcome, 
and 0 indicating that the unit did not have the outcome), and Z be an indicator of 
treatment status (with a value of 1 indicating that the unit received the treatment, and 0 
indicating that the unit did not receive the treatment), then our two potential outcomes, in 
formula form, are: | = 1, and | = 0.  We shorten this notation to (1)and (0).  
Then the “treatment effect” for a particular unit i is (1) − (0).  We call this the 
                                                          
1 Actually it is more precise to say that there is one potential outcome for every possible treatment.  
However, throughout this paper we will focus on the binary treatment case only. 
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“potential outcomes framework” because, for any given unit i, we can observe only (1) 
or (0), but not both2.  Holland refers to this situation as the “Fundamental Problem of 
Causal Inference” (1986).   
1.3 Two types of treatment effects. 
The goal for much research, particularly biomedical research, is to describe the 
causal effects of different treatments.  To make accurate measurement and estimation 
possible, we need to be very precise in defining terms.  We distinguish between two3 
types of causal effects for clear communication and analytical accuracy.  These are the 
average treatment effect (ATE) and the average treatment effect among the treated 
(ATT).  In short, the ATE is the effect if the treatment of interest were applied to the 
entire target population as compared to the entire population receiving the control, while 
the ATT is the effect of the treatment only within the treated population. 
These two treatment effect measurements can be expressed in the following formulas: 
               
 
As noted by Austin (2011), with experimental data (more explanation on the difference 
between experimental and observational data below), these two measures of treatment 
effect are equal, on average, because by design and the application of randomization, 
                                                          
2 Even in cases of repeated measures or crossover designs within a RCT, the different orderings of 
treatment and control status for a particular subject is fixed.  These designs are outside the scope of this 
paper, but the emphasis here is that, obviously, we can only observe one actual course of events, and thus 
we still have a counterfactual outcome to estimate to determine subject-specific effects. 
3 A third type, the average treatment effect in the untreated, is mentioned by Williamson et al. (2012), but 
is unaddressed in most of the literature, and indeed would seem rarely to be pragmatically interesting.  It is 
not explored in this paper. 
= [ (1) − (0)]
= [ (1) − (0)] 
= [ (1) − (0)| ]
= 1] 
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there is no systematic difference in the treatment and control groups.  Meanwhile with 
observational data, these two measures may differ because there may be a systematic 
difference in which units received the treatment and which units received the control. 
In this analysis, due to the research goals for the case study analysis, which will 
be further explained in Section IV, we focus on the ATE. 
1.4  Covariates and confounders. 
Of course, things are not quite as simple as just computing the average outcome 
measures in the different treatment groups and then comparing them (either through a 
risk difference, or a relative risk, or an odds ratio).  Other circumstances and 
characteristics may be influencing the levels of the outcome measure and the selection of 
sample units into the different treatment groups.  We attempt to quantify these “other 
circumstances and characteristics” through measurements on additional variables, called 
covariates, taken before or at the same time as the treatment.  Figure 1 below illustrates 
the causal relationships among confounders, treatment and outcome.  The relationship 
between treatment and outcome (represented by the dashed arrow from Z to Y) is 
generally the central research question; however, that relationship is obscured by the 






Figure 1.  Relationships among confounders, treatment, and outcome. 
(Dashed line indicates relationship of primary research interest) 
 
 
Figure 2 presents a modified causal diagram that highlights the various types of 
covariates and their relationships to the treatment variable and the outcome variable.  The 
oval labeled “X1” represents confounders, i.e., those covariates related to both treatment 
and response.  The oval labeled “X2” represents variables related to response only; “X3” 
represents variables related only to treatment; and “X4” represents variables related to 
neither treatment nor response.  Although not frequently mentioned in the literature, it is 
entirely possible and probably common in observational data to have X4 type variables in 
the dataset.  Determining which covariates fall into each of these four categories can be 
challenging, particularly in high dimensional datasets.  (In later sections of this paper we 
will frequently refer to the different variable types simply by their label in Figure 2, e.g., 
“X3 variables” instead of “variables related to treatment only.”) 
Figure 2.  Causal diagram highlighting 4 types of covariates. 


























1.5 Experimental vs. observational data 
In biomedical research, a randomized controlled trial (RCT) is considered the 
“gold standard” of research methods, applying careful design decisions, sensitive 
measurement techniques, and sophisticated analysis methodologies in order to rigorously 
apply the scientific method to draw logical inferences regarding the relationships among 
specified treatments, covariates, and outcomes.  The key feature of an RCT is the 
application of randomization in the assignment of units to the treatment groups. 
Yet in many circumstances experimental studies are simply not an option.  Cost, 
practicality, or ethics may imply that an RCT is either impossible or sub-optimal.  In 
these cases, research can often still proceed by leveraging observational data. 
What are the benefits of an observational study?  First, data is often much easier 
and less expensive to come by.  Second, many ethical issues are avoided.  For example, if 
a researcher wants to be able to estimate the (detrimental) effect of some harmful 
behavior, such as smoking, it is not ethical to set up an experiment in which one group of 
human subjects would be assigned to receive the “smoking” treatment.  Third, there are 
many cases where it is not just more difficult, but it is actually impossible to construct an 
RCT for the specific research question.  Thus, for many scientific research questions to 
advance, observational data must be leveraged. 
However, using observational data carries a significant challenge.  The 
fundamental objective of much scientific research is to draw conclusions about causal 
relationships.  An RCT supports the logical reasoning about causal relationships because 
that type of study carefully controls which covariates vary, and by how much, in the 
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experimental data.  Furthermore, because of the randomization involved in the process of 
assigning units to treatment groups, both measured and unmeasured covariates are in 
theory balanced among the treatment groups.  The non-randomized study enjoys no such 
benefits, and the logical support for causal conclusions may be tenuous.  Selection bias of 
subjects and unmeasured covariates are very real issues.  As one example: a blood 
pressure drug may be studied for its effect on decreasing blood pressure by interviewing a 
sample of physicians known to prescribe the drug.  The results may show that the drug of 
interest appears to reduce blood pressure by more than an alternative drug.  Yet that result 
could be due to the physicians systematically prescribing the drug to patients with higher 
baseline blood pressures; such patients may show more decrease in blood pressure from 
any similar drug, simply because they start off with a higher blood pressure on average.  
With this type of selection bias involved, we cannot really conclude anything about the 
performance of the drug of interest relative to the other drug. 
In the above, it was stated that the treatment Z could be a control status, or some 
other alternative “baseline” treatment.  In this, we are facing the same fine distinction 
lucidly delineated by Holland (1986); he states that  
[T]he effect of a cause is always relative to another cause.  For example, the 
phrase ‘A causes B’ almost always means that A causes B relative to some other 
cause that includes the condition ‘not A.’  The terminology becomes rather 
tortured if we try to stick with the usual causal language, but it is straightforward 
if we use the language of experiments – treatment (i.e., one cause) versus control 
(i.e., another cause) (p. 946). 
So, in our example above, the effect of the blood pressure drug under study may be 
relative to the absence of any drug, or it may be relative to the effect of an established (let 
us say standard) treatment.  It will simplify our exposition to refer to the two treatments 
simply as “treatment” and “control,” but it should be understood (and is in fact the case in 
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our case study described later) that the “control” may be simply a different treatment – 
the “not A” condition Holland describes. 
1.6 Propensity score methodologies: Enabling causal inference from 
observational data. 
More than 30 years ago, Rosenbaum and Rubin (1983) formalized a methodology 
in which the probability of a subject’s treatment group is determined as a function of the 
measured covariates for that subject.  Conditioning subsequent analysis on this 
probability enables unbiased estimation of the average treatment effect.  Bias due to 
unmeasured covariates may still exist.  In the Methods section we will go into greater 
detail about the propensity score and its associated methodologies.  For now, the key idea 
is that this constitutes a method for handling the limitations inherent in observational data 
described above; multiple covariates can be effectively summarized into one scalar 
measure, a score.  Then, conditioning properly on this score, one may obtain unbiased 
estimates of treatment effects.  The insights articulated by Rosenbaum and Rubin in 1983 
(and extended and refined in subsequent papers, both by them and by other authors) have 
proved immensely beneficial for the goal of gleaning causal inferences from 
observational data. 
In the next section of this paper, we will define propensity scores in depth, explain 
the process for estimating them and how to evaluate those estimates, examine several 
ways that treatment effects are estimated using propensity scores, and highlight certain 









The propensity score is defined by Rosenbaum and Rubin (1983) as the 
probability of receiving the treatment given the covariates, which is expressed as 
( ) = Pr( = 1| ). 
It should be noted that the propensity score as defined by Rosenbaum and Rubin 
(1983) implies a treatment with exactly two levels, such as treatment versus control, or 
new therapy versus standard therapy.  Imbens (2000) extended the concept to multi-level 
treatments; for our purposes in this paper, however, we will restrict attention to only 
binary treatment scenarios. 
The propensity score is a balancing score.  This means that, conditional on the 
propensity score, the distribution of all covariates is the same in the treatment group as in 
the control group.  If ( ) is a balancing score, then ⊥ | ( ).  An important result is 
that 
if treatment assignment is strongly ignorable [see next paragraph] given X,… then 
the difference between treatment and control means at each value of a balancing 
score is an unbiased estimate of the treatment effect at that value, and 
consequently pair matching, subclassification, and covariance adjustment on a 
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balancing score can produce unbiased estimates of the average treatment effect 
(Rosenbaum and Rubin 1983) (italics added). 
2.2 Assumptions. 
Several assumptions are involved with the application of propensity scores.  First 
is the assumption of “strongly ignorable treatment assignment” (SITA).   There are two 
aspects to this.  The first is the assumption that the response of a unit is conditionally 
independent of its treatment group, given its covariates: ( (1), (0) ⊥ | .  The second 
aspect is elsewhere referred to as “positivity” (e.g.,  Williamson et al., 2012; Cole and 
Hernan, 2008; and Funk et al., 2011) and is the notion that every unit has a positive 
probability of being assigned to either treatment group: 0 < Pr( = 1| ) < 1.  Austin 
(2011) notes that this SITA assumption is common to other statistical methodologies 
beyond propensity score methods, such as regression-based approaches. 
Many authors, such as Austin (2011), Funk,  et al. (2011), Hirano and Imbens 
(2001), Lunceford and Davidian (2004), and Rosenbaum and Rubin (1984), highlight the 
fact that the SITA assumption is the same as an assumption of no unmeasured 
confounders; in other words, all covariates that are related to both the outcome and the 
treatment are measured and included in the propensity score model.  This is a strong 
assumption, and it is in fact untestable, because it is an assumption about unmeasured 
variables (McCaffrey et al., 2013).  If unmeasured confounders do exist, then estimates 
from propensity score methods (and other methods, for that matter) may be biased, and 
the more so as those nonmeasured confounders are less correlated with the other 
confounders (Funk et al., 2011). 
12  
Another major assumption of propensity score methodologies is the Stable Unit 
Treatment Value Assumption (SUTVA).  This is the assumption that the treatment effect 
for one individual is not affected or influenced by the treatment status of another.  It is a 
necessary assumption for limiting the potential outcomes for analysis, as without it, we 
would need to consider the two potential outcomes for unit i conditional on the treatment 
assignments for every other unit.   Little and Rubin (2000) point out that “[w]ithout some 
such exclusion restrictions (to use the language of economists) which limit the range of 
potential outcomes, causal inference is impossible.  Nothing is wrong with making 
assumptions…. The quality of these assumptions, not their existence, is the issue” (p. 
123). 
2.3 Typical propensity score analysis process. 
Figure 3,  below, illustrates the typical propensity score analysis process, 
assuming as a starting point that observational data have been collected and are ready for 
analysis.  First, covariates are evaluated for their initial balance before adjustment.  Then, 
the propensity scores are estimated for each unit, and the adjusted balance of the 
covariates is assessed.  These two steps are iterated as necessary to achieve satisfactory 
covariate balance.  Finally, treatment effects are estimated using the estimated propensity 






Figure 3.  Typical propensity score analysis process. 
 
2.4 Assessing balance of covariates. 
It was stated in the previous section that the propensity score is a balancing score, 
and in Figure 3 above it is indicated that covariates should be examined for balance 
between the treatment and control groups both before and after adjustment for the 
propensity score.  In this section we describe several approaches for assessing this 
balance; fundamentally, this step comes down to applying graphical and/or quantitative 
techniques for assessing the similarities of distributions in two different groups, much as 
might be done in an exploratory data analysis. 
Within graphical approaches, the most common tool employed for assessing 
balance is boxplots (Austin and Stuart, 2015).  Austin and Stuart advise that empirical 
cumulative distribution functions can also be used.  Others, such as Rosenbaum and 
Rubin (1984), use simple bar charts to compare the means and proportions of particular 
covariates within subclasses, or strata, defined on the propensity score quintiles.  It 
should be noted, however, that the covariates for treatment and control groups after 
balancing on the propensity score should be balanced on their entire distributions, not 
Evaluate Covariate Balance
Estimate Propensity Scores







solely their means or medians (Austin 2011), so bar charts may not be sufficiently 
informative. 
Within quantitative approaches, a recommended approach is to compute the 
standardized mean difference (SMD) for each covariate (also called the “standardized 
bias,” as in Harder et al. (2010)).  Note that this metric may also be viewed in terms of its 
absolute value, i.e., the ASMD.  As given in Austin (2011), the SMD is computed for 
continuous covariates as: 
= ( ̅ − ̅ )+2
 
and for dichotomous covariates as: 
= ( ̂ − ̂ )̂ (1 − ̂ ) + ̂ (1 − ̂ )2
 
where the subscripts t and c stand for treatment and control, respectively.  Categorical 
variables with more than two levels may be expressed via a series of dichotomous 
dummy variables, and then the balance assessed on those dummy variables.  Note that the 
above formulae are for unweighted comparisons.  If propensity scores have been 
estimated and the inverse probability of treatment weighting application method (see 
below) is used, then the propensity score-adjusted SMD may be computed by using the 
weighted means and variances in the above formulae (Austin and Stuart 2015). 
There is no strong consensus as to what SMD threshold indicates a variable is 
sufficiently balanced.  Austin (2011) and Austin and Stuart (2015) have suggested 0.1 is a 
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good threshold and indicated that other authors have advised that level as well, while 
Harder (2010) employed 0.25 in an empirical study, but suggested that for very important 
confounders (i.e., those highly related to the outcome), a lower threshold may be 
preferable.   
Another quantitative approach is to use F statistics ((D'Agostino 1998), 
(Rosenbaum and Rubin 1984)) or some variation (t tests, Kolmogorov-Smirnov statistic) 
to assess the balance of covariates. 
2.5 Estimating propensity scores and variable selection. 
The second step illustrated in Figure 3 is to estimate the propensity score.  The 
true underlying propensity score, the probability of selection into the treatment group 
given the covariates, is never definitely known.  We must estimate it.  Building a model 
for estimating the propensity score is not a trivial task.  Several methodologies may be 
used here, although logistic regression and the nonparametric Generalized Boosted 
Model (GBM) are perhaps the two most common.  Within logistic regression, which is 
the methodology of focus in this paper, there are multiple decisions related to which 
covariates to include and whether to include interactions or higher order terms of 
covariates. 
Many authors, including among others Austin (2011), Brookhart et al. (2006), 
Emsley et al. (2008), Harder (2010), and Rosenbaum and Rubin (1984), have explored 
the question of which covariates are important to include in a logistic regression model 
for estimating the propensity scores.  Some difference in opinion is evident in the 
literature (Millimet and Tchernis 2009).  A few authors, such as (Emsley et al. 2008) say 
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that including all measured covariates in the propensity score model is the simplest 
approach and enhances the precision of the effect estimates, and while it may introduce 
some bias into the eventual treatment effect estimates, the bias introduced is small and so 
the “cost” is low.  Other authors, such as (Brookhart et al. 2006), have performed 
simulations that illustrate that including all confounders and all variables related to 
outcome only (i.e., the X1 and X2 variables in Figure 2) is required for obtaining the least 
biased estimates of treatment effect, and as long as the confounders are included, the 
inclusion of X3 variables (those related to treatment only) will have only a modest effect 
on the MSE by increasing the variance modestly4. 
This latter view seems to be the prevailing view, although our current research did 
not attempt to evaluate the prevalence of each approach either in reviews, or tutorials, 
empirical/simulation studies, or real life data applications.  Our sentiment is that part of 
the analyst’s job is to categorize all measured covariates into the X1, X2, X3, or X4 type 
covariates defined in the Introduction section; thus, since there seems to be general 
agreement that including X1 and X2 variables in the propensity score model is optimal5, 
only these two types of variables should be used.  Nevertheless, given that it is not always 
straightforward to categorize covariates into these four types, particularly in high 
dimensional datasets, it is reassuring, although perhaps worthy of further theoretical 
testing and sensitivity testing in specific applications, that the inclusion of X3 type 
                                                          
4 Relevantly, Brookhart et al. (2006) also indicate that the relative impact on the treatment effect estimator 
under various propensity score specification models depends to an extent on the propensity score 
application method (matching, stratification, etc.) that is used.  In their simulations, they found that the 
stratification (subclassification) method was more sensitive to the misspecification of the propensity score 
model, in terms of effect on MSE, than was the cubic regression spline method. 
5 Even if not very optimal, due to low cost of including X3 variables as long as all X1 variables are 
included. 
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covariates seems to pose little risk to subsequent treatment effect estimation.  Our 
simulation analysis described below appears consistent with this approach. 
When building a logistic regression model to estimate the propensity scores, a 
further question presents itself, namely, what sorts of interaction or higher order terms 
should be used?  In order to answer this, we feel it is important at this point to emphasize 
the purpose of the propensity score. 
In the preceding discussion, we find it interesting (and believe it critical) to 
remember that the objective of the propensity score model is not to make the best 
predictive model of treatment group (Rubin 2004).  In fact, one can hypothesize a 
propensity score model that perfectly predicts treatment group assignment based on the 
covariates.  In this case, given a unit’s vector of covariates, the probability of assignment 
to the treatment group for that unit would be either 0 or 1.  This would be a perfectly 
predictive model, and, under normal regression purposes, a highly “successful” model.  
Yet, in the paradigm of propensity scores it would be a useless model.  There would be 
no ability to estimate average treatment effect from the data if the treatment group were 
perfectly determined by the covariates.  It is the same as saying that in an RCT in which 
only males received the test treatment, one could not make conclusions about the effect 
of the treatment on females, unless one makes the assumption that the effect of the 
treatment would be exactly the same on males and females.  But RCTs are not designed 
to provide the treatment to only males, if females are also in the target population.  RCTs, 
by design, ensure that covariates are balanced across treatment groups, and randomization 
assures us that, on average, unmeasured covariates/confounders will be balanced as well.  
Instead of a perfectly predictive propensity score model, we want a model that results in 
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balancing the covariates across the treatment groups.  Rubin (2004) even points out that 
traditional regression diagnostics are not relevant for evaluating a propensity score 
model. 
Having reinforced the fundamental objective of the propensity score model, 
namely to balance the covariates across the treatment groups, we can consider the 
question of variable selection for the propensity score model in a different light.  A 
practical approach is to include in the propensity score model first all main effects for all 
measured covariates.  Any covariates known a priori to be unrelated to the outcome 
could be omitted, but if there is uncertainty, they should be included.  For any covariates 
that remain unbalanced after adjustment on the initial propensity score, interaction and 
higher order terms may be added to the propensity score model.  This leads to the 
iterative process diagrammed in Figure 3.  After each revision of the propensity score 
model, balance on all important covariates should be inspected, and a decision should be 
made whether the covariates are sufficiently balanced or not.  Note that Harder et al. 
(2010) make the eminently reasonable suggestion that the balance required need not 
necessarily be the same for all covariates; covariates strongly related to outcome or 
treatment likely require a higher degree of balance, but covariates unrelated, or very 
weakly related, particularly to the outcome, may not need to be stringently balanced. 
2.6 Typical approaches for applying propensity scores. 
After propensity scores are estimated and covariates are deemed sufficiently 
balanced, the next step is to return to what is the main objective of the study: estimating 
average treatment effects.  Several approaches can be used, and we next describe four 
that are highly prevalent in the literature.  We will refer to these as propensity score 
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application methods, to distinguish this analysis step from the modeling of the propensity 
scores themselves.  Harder et al. (2010) point out that any of the propensity score 
modeling methods (such as logistic regression, or generalized boosted models) may be 
paired with any of these application methods, leading to quite a number of potential paths 
that could be taken in a propensity score-based analysis. 
In the following we are assuming a binary outcome, since that is the scenario for 
our case study data analysis and hence our simulation analysis. 
Inverse probability of treatment weighting (IPTW) and Doubly Robust (DR).  
Each individual unit in the sample may be given a weight based on the propensity score.  
The weight is equal to the inverse of the probability of the treatment which that unit 
actually received (Rosenbaum 1987).  Thus, for units in the treatment group, the weight 
is 1/ ( ), while for units in the control group, the weight is 1/(1 − ( )).  This can be 
expressed as a single formula for both groups as (Austin 2010): 
= + 1 −1 − . 
The IPTW estimate of average treatment effect (in terms of the risk difference) is: 
= 1 ̂ −
1 (1 − )
(1 − ̂ ) . 
The doubly robust (DR) estimator, introduced by Lunceford and Davidian (2004), 
also involves weights based on the propensity score.  In this method, the treatment effect 
is estimated via a combination of weights and an outcome regression model that relates 
outcome to the treatment variable and covariates.  The name of the method refers to its 
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property of providing an unbiased estimate of treatment effect as long as either the 
propensity score model or the outcome regression model is correctly specified.  To 
contrast the two methods, in the IPTW method above, if the propensity score model is 
misspecified, the treatment effect estimates will likely be biased.  In the DR method, if 
the propensity score model is misspecified, then if the outcome regression model is 
correctly specified then the treatment effect estimates will still be unbiased.  Lunceford 
and Davidian highlight that the analyst has “two chances” to specify a correct model.  
The DR estimate of average treatment effect is (Austin 2010): 
= 1 − ( − ̂ ) ( , )̂ −
1 (1 − ) − ( − ̂ ) ( , )
(1 − ̂ ) , 
where ( , ) = ( | = , ).  In other words, ( , ) and ( , ) are the 
regressions of the response variable on the set of covariates  in the treatment and 
control groups, respectively. 
Note that in both the IPTW and the DR application method, estimated propensity 
scores are used, because there is no way for us to know the true scores.  Therefore we 
have estimated weights.  This leads to some complexity in specifying the variances for 
these treatment effect estimators.  Using bootstrapped estimates of the standard error of 
the estimator is recommended (Funk et al. 2011). 
Stratification.  In stratification (also called subclassification), observations in the 
sample are divided into k strata based upon the quantiles of the estimated propensity 
score.  After the observations are divided into strata, the treatment effect is estimated 
within each stratum, and the several stratum-specific treatment effect estimates are 
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combined in a weighted average to estimate an overall treatment effect.  The stratification 
estimate of average treatment effect is (Austin 2010): 
= 1 ( , − , ), 
where ,  and ,  represent respectively the proportion of treated and control 
observations in the ith stratum that experience the outcome. 
The variance of this estimator is obtained by pooling the stratum-specific 
variances: 
( ) = 1 , 1 − ,
,
+ , 1 − ,
,
. 
Several practical decision points and challenges do arise in the subclassification 
methodology.  How many strata and where to draw the strata boundaries are two key 
decisions.  The number of strata (k) can really be any number but is typically five, as it 
was shown by Cochran (1968) that stratification on five levels of a covariate removes 
90% of the bias from that covariate.  The strata boundaries are often set at the quintiles of 
the distribution of the estimated propensity score.  This of course would imply that the 
total number of observations, treatment plus control, would be equal in each stratum.  
This in turn means that each stratum would receive equal weight in the estimation of 
ATE, which somewhat simplifies calculations.  However, in cases where many 
observations in the control (treatment) group have a very low (high) propensity score, it 
could happen that defining the strata on the quintiles of the propensity scores of the full 
sample results in some strata having only control (treatment) observations.  This situation 
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leads to a significant philosophical conundrum.  On one hand, it seems reasonable to 
exclude control observations having very low propensity scores, when there are no 
treatment observations having similarly low propensity scores, because this is evidence 
that those controls are not in fact comparable to the treatment observations after 
adjustment for the covariates, and our reason for using propensity scores is to discern the 
treatment effect after adjustment for covariates.  On the other hand, excluding a set of 
control observations like this would have two effects.  First, the statistical power would 
be decreased, due to the lower sample size, making it more difficult to detect true 
treatment effects.  Second, one could not really claim to be estimating the ATE anymore, 
since some types of controls were systematically excluded from comparison.  Rather, 
assuming there remained enough controls to make treatment effect estimates with the 
treatment group observations, this must be interpreted now as an ATT estimate, average 
treatment effect among treated; and this may not be the effect that is desired from the 
study. 
Matching.  In propensity score matching, each treatment observation is matched 
to one or more control observations that are most like it in terms of the collective set of 
covariates, in other words, most similar in terms of ( ).  The treatment effect for every 
individual in the treatment group is then estimated by direct comparison against its 
match(es) on the outcome measure, and the multiple individual treatment effects are 
averaged for a population estimate. 
While conceptually straightforward, propensity score matching does present 
challenges.  The matching may be done in a number of ways.  Each treatment observation 
may be matched to just one control or to several controls.  Matching may be done without 
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replacement (once a control is matched to a treatment observation, it is unavailable for 
further matches) or with replacement.  Determining which controls are “closest” can be 
approached in different ways, for example by using nearest neighbor matching, 
Mahalanobis metric matching, or nearest neighbor Mahalanobis metric matching within 
calipers (D'Agostino 1998).   
It should be noted that the treatment effect estimate available from the matching 
application is the ATT, the average treatment effect among the treated (Imbens 2004).  
This is because an estimate is made for the treatment effect of each treated unit in the 
sample, but unmatched controls are not used.  In this paper, we therefore do not use the 
matching application method, because our case study research objectives imply that it is 
the ATE that is of primary interest. 
Covariate adjustment (i.e., regression).  Another common method for employing 
propensity score analysis is to regress the outcome measure on the propensity score and 
the treatment group variable.  This is a common approach in the medical literature.  If the 
outcome measure is binary, then logistic regression would be the natural choice; 
however, as highlighted by Austin (2010), with logistic regression the odds ratio, not the 
risk difference, is the estimated effect. 
Given the objectives of the case study, the analysis in this paper employs the first 
three of these methods only, i.e., IPTW, DR, and stratification.  Now having defined 
propensity scores, explained assumptions and properties of the methods, described typical 
analysis procedures and application methods, we proceed to describe the simulation study 








We had three main objectives with this simulation.  First, because our sample size 
in our case study was small (less than 100 total observations), we wanted to understand 
the impact of sample size on propensity score-based methods with respect to bias and 
variance of estimators.  Second, we wanted to test which of three propensity score-based 
methods appeared to be best under varying conditions of misspecifying the propensity 
score model.  Third, we wanted to assess confidence interval coverage for the different 
methods using the bootstrap estimate of the standard error.  These objectives would all be 
instructive with respect to how we might want to analyze our case study data. 
3.2 Data generating process. 
In the nomenclature of Figure 2, we had three sets of simulated covariates, {X1}, 
{X2}, and {X3}.  The set {X1}, the confounders, contained two variables, one a 
continuous variable with a standard normal distribution and the other a binomial variable 
with p = 0.5.  The set {X2}, the prognosticators (related to outcome but not to treatment), 
also contained two variables, with same distributions as those in {X1}.  Finally, {X3} 
contained a single variable, distributed as standard normal.  This was related to treatment 
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but not to outcome.  These five covariates and their distributions, along with their 
relationships to Z and to Y are all summarized in Table 1. 
For each observation in the simulated datasets, we first generated the five 
covariates described above.  {X1} and {X3} were then used together with specified beta 
parameters (see below) to compute the logit(Pr(Z=1)) for each observation.  From this 
value, Pr(Z = 1) was computed, and then Z was generated as a binomial value with p = 
Pr(Z = 1). 
Having generated the treatment variable, the outcome variable Y for each 
observation was generated in a similar fashion, but this time, {X1} and {X2} variables 
were used, along with Z and specified alpha parameters (see below) to compute the 
logit(Pr(Y=1|X1, X2, Z)) for each observation.  From this value, Pr(Y = 1|X1, X2, Z) was 
computed, and then Y was generated as a binomial value with p = Pr(Y = 1|X1, X2, Z). 
Table 1.  Covariate distributions and parameters for simulation analysis. 
 
Two sample size settings were tested, n = 100 and n = 1000.  For each setting, 
1000 simulated datasets were generated.  For each dataset, eight propensity score models 
were tested.  In all models, logistic regression was used to estimate the propensity scores; 
Covariate 
Set Variable Distributed As: Related to:
Covariates {X1} x1.1 N(0, 1)
x1.2 Binomial(0.5)
{X2} x2.1 N(0, 1)
x2.2 Binomial(0.5)
{X3} x3 N(0, 1) Treatment only
Treatment Z
Outcome Y
Note: The parameter value of 1.25 for       represents an odds ratio of approximately 3.5 for the treatment effect.
Together with the other parameters and covariates, this equates to a true risk difference  of approximately 0.2.
Treatment & Outcome
Outcome only
( | , ) = + . . + . . + . . + . . +
( | ) = + . . + . . +
 ( , . , . , . , . , ) = (−1, 1, 1, 1, 1, 1.25)
 , . , . , = (−0.5, 1, 1, 1)
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the models varied according to which covariates were included in the logistic regression 
model.  Table 2 summarizes the eight models.  Note that Model 4 is the “correct” model 
in that it contains exactly {X1} and {X3}; Models 2, 3, 4, and 5 all contain {X1}, i.e., the 
confounders.  Models 1, 6, 7, and 8 do not contain the confounders, although Models 7 
and 8 do contain {X3}. 
Table 2.  Propensity score model specifications. 
 
For each simulated dataset, and under each of the eight propensity score model 
specifications, we applied four propensity score application methods: IPTW, DR, 
DR.MIS, and Stratification.  DR is the doubly robust method with the outcome regression 
model correctly specified as: 
( | , ) = + . . + . . + . . + . . +   
DR.MIS is the doubly robust method with the outcome regression model misspecified as: 
( | , ) = + . . + . . +   
In DR.MIS, one continuous covariate and one dichotomous covariate have been left out 
of the outcome regression model. 
3.3 Results. 
The results from our simulation study will inform some of our decisions related to 
how we perform the analysis of the case study data (see Section IV).  The specific details 
Model #: 1 2 3 4 5 6 7 8
Model Type: Intercept only Confounders Included No Confounders
Covariates included: NONE X1 X1X2 X1X3 X1X2X3 X2 X3 X2X3
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of the data generating process were presented in the previous section.  To give an idea of 
the type of dataset that was generated after all those steps were followed, we selected one 
of the randomly simulated datasets.  Table 3, below, compares distributional statistics for 
all five covariates within levels of the treatment variable and within levels of the outcome 
variable, providing a baseline assessment of how similar the treatment groups and 
outcome groups are with respect to each covariate. 
Table 3.  Baseline distribution of covariates for randomly selected simulated dataset. 
 
We observe that for a typical dataset simulated through the process described 
above, we have five covariates (three continuous and two binary), one binary treatment 
variable, and one binary outcome variable.  From the left half of Table 3, we see that 
x1.1, x1.2, and x3 seem associated with treatment (low p-values and high standardized 
mean differences).  Meanwhile, x2.1 and 2.2 do not appear associated with treatment.  
These observations accurately reflect how the covariates, treatment, and response 
variables were generated.  From the right half of Table 3, we see that all covariates and 
treatment appear associated with outcome, due to low p-values and high SMDs.  We note 
that in the true model, x3 is not associated with outcome.  We also note that, while its p-
value is very low at 0.001, its SMD shown in Table 3 is the lowest of all the covariates.  
As one final note with respect to this representative simulated dataset, we point out that 
Stratified by Treatment (Z) Stratified by Outcome (Y)
0 1 p SMD 0 1 p SMD
n 512 488 376 624
CONTINUOUS 
VARIABLES x1.1 (mean (sd)) -0.30 (0.90) 0.36 (0.94) <0.001 0.718 -0.46 (0.88) 0.32 (0.91) <0.001 0.86
x2.1 (mean (sd))  0.03 (1.01) 0.05 (0.97) 0.805 0.016 -0.34 (0.96) 0.26 (0.93) <0.001 0.637
x3 (mean (sd)) -0.42 (0.91) 0.38 (0.91) <0.001 0.877 -0.16 (0.94) 0.05 (1.02) 0.001 0.211
CATEGORICAL 
VARIABLES x1.2 = 1 (%)   216 (42.2)  292 (59.8) <0.001 0.359   126 (33.5)  382 (61.2) <0.001 0.578
x2.2 = 1 (%)   262 (51.2)  239 (49.0) 0.528 0.044   150 (39.9)  351 (56.2) <0.001 0.332
Z = 1 (%)   104 (27.7)  384 (61.5) <0.001 0.725
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the crude, unadjusted estimate for the average treatment effect in terms of the risk 
difference is 0.318; the treatment group has a probability of a positive outcome that is 
0.318 higher than that of the control group (see Appendix Table A1). 
Next, we explore results for the full set of 1000 iterations.  Our first objective with 
this simulation study was to understand the impact of sample size on propensity score-
based methods with respect to bias and variance of treatment effect estimators.  Table 4 
presents the simulation results in terms of MSE, Bias, and Variance, for the IPTW 
propensity score application method.  By comparing adjacent rows, we can make the 
following observations: (1) Increasing the sample size 10-fold (from 100 to 1000) had no 
notable impact on the bias of the estimates (differences in bias seen in the table for the 
same propensity score model specification are due solely to random sampling variations). 
Table 4.  MSE, Bias, and Variance for IPTW method for n=100 vs n=1000. 
 
(2) Increasing the sample size 10-fold decreased the variance by a factor of a little over 
100 for propensity score models including X1, while for models excluding X1 it 
decreased the variance by a factor of over 300.  (3) Consequently, increasing the sample 
size 10-fold decreased the MSE by a factor of a little over 100 for propensity score 
models including X1, while for models excluding X1 it decreased the MSE by a factor of 
Propensity Score Model
Int. only Confounders Included No Confounders
NULL X1 X1X2 X1X3 X1X2X3 X2 X3 X2X3
IPTW MSE n100 0.2829 0.1237 0.1192 0.2810 0.3069 0.2746 0.3564 0.3593
n1000 0.0216 0.0011 0.0009 0.0026 0.0025 0.0214 0.0278 0.0276
BIAS n100 0.1409 -0.0004 0.0001 -0.0017 0.0004 0.1416 0.1573 0.1604
n1000 0.1441 0.0011 0.0009 0.0008 0.0005 0.1438 0.1637 0.1633
VAR n100 0.2630 0.1237 0.1192 0.2810 0.3069 0.2546 0.3316 0.3336




around 13.  The lower decrease in MSE when moving from a sample size of 100 to a 
sample size of 1000 for propensity score models excluding X1 is explained by the fact 
that these models have substantially more bias (which remains unchanged by increasing 
sample size).  Since = + , for biased estimators the bias, 
being a quadratic term, has a relatively large effect on MSE as compared to the variance.  
Therefore, even though the variance decreased substantially with the increase in sample 
size, the bias component prevented the MSE from decreasing to a similar degree. 
Table 4 above presents the results for the IPTW propensity score application 
method only.  Table A3 in the Appendix presents the results for all four application 
methods tested in this simulation.  The pattern described above is completely consistent 
for each of the four propensity score application methods tested6; thus, for brevity and 
clarity, we confine our subsequent analysis solely to the scenarios with sample size 1000. 
Before comparing the four propensity score application methods, we demonstrate 
how the balance of the covariates between the treatment groups may be reassessed after 
adjusting for the propensity score.  Table 3 earlier showed the unadjusted SMD for each 
of the covariates.  Variables x1.1, x3, and x1.2 were significantly unbalanced with respect 
to the treatment, Z.  Table 5, below, shows the SMDs after weighting by the propensity 
score.  Note that the SMDs shown for Model 1, the intercept only or null propensity score 
model, match the SMDs shown in the 4th column of Table 3 above.  In every scenario 
where the X1 variables were included in the propensity score model specification, the 
adjusted SMDs for x1.1 and x1.2 are below 0.2 – and they are usually well below 0.10.   
                                                          
6 With an apparent exception, that yet actually follows the description above.  See Appendix Table A3 
footnote. 
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Table 5.  Standardized Mean Differences, w/ respect to treatment group (Z), weighted by 
propensity score (for one representative simulated dataset). 
 
Likewise, in every scenario where X3 is included in the propensity score model 
specification, the adjusted SMD for that variable is very low, always below 0.03.  Finally, 
in Model 5, which includes all three types of covariates, all five of the variables have an 
adjusted SMD less than 0.20.  These points demonstrate that, for this relatively 
noncomplex simulated dataset, summarizing multiple covariates into one scalar score can 
effectively serve to balance those covariates in the treatment groups. 
Next, we turn to our second objective of the simulation analysis, comparing the 
three different propensity score application methods in terms of MSE, Bias and Variance 
for the different specifications of the propensity score model.  Table 6 below has an 
identical structure to Table 3 above, but includes all propensity score application methods 
and suppresses the results for the smaller sample size datasets (see Table A3 in the 
Appendix for those results).  Note that for the second propensity score application 
method, the doubly robust (DR) method, we actually tested two different scenarios.  In 
the first scenario, the outcome regression model was correctly specified.  In the second 
scenario, the outcome regression model was misspecified by omitting two covariates that 
were truly related to the outcome.  This may be a better representation of real-life 
Propensity Score Model
Int. only Confounders Included No Confounders
1 2 3 4 5 6 7 8
NULL X1 X1X2 X1X3 X1X2X3 X2 X3 X2X3
CONTINUOUS 
VARIABLES x1.1 0.718 0.009 0.018 0.142 0.163 0.718 0.833 0.833
x2.1 0.016 0.022 0.021 0.009 0.086 0.000 0.020 0.000
x3 0.877 0.981 0.979 0.029 0.014 0.874 0.022 0.021
CATEGORICAL 
VARIABLES x1.2 0.359 0.014 0.010 0.018 0.023 0.358 0.432 0.431
x2.2 0.044 0.054 0.020 0.028 0.065 0.000 0.004 0.012
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analysis in that we usually do not know with certainty if our regression model is correctly 
specified. 
Table 6.  Varying propensity score application method and propensity score model 
specification. 
 
Our first observation from Table 6 is that the Doubly Robust (DR) method 
consistently has the lowest MSE, and the misspecified DR model, DR.MIS, consistently 
has the second lowest MSE, both regardless of propensity score model specification.  For 
scenarios where the propensity score model includes X1 variables (Models 2, 3, 4, and 5), 
the differences in MSE across the methods is quite small, but for the models without the 
confounders (Models 1, 6, 7, and 8) the differences in MSE are substantial between 
IPTW/STRAT and DR/DR.MIS methods. 
The fact that the bias for the DR method is effectively zero for all propensity 
score model scenarios is a demonstration of the doubly robust property of this method.  
Even for propensity score models that were misspecified (i.e., all except for Model 4), the 
estimators are unbiased.  This is because in this method, the outcome regression model is 
correctly specified.  In the DR.MIS method, the outcome regression model is 
Propensity Score Model
Int. only Confounders Included No Confounders
Propensity Score 1 2 3 4 5 6 7 8
Application Method NULL X1 X1X2 X1X3 X1X2X3 X2 X3 X2X3
IPTW MSE n1000 0.0216 0.0011 0.0009 0.0026 0.0025 0.0214 0.0278 0.0276
BIAS n1000 0.1441 0.0011 0.0009 0.0008 0.0005 0.1438 0.1637 0.1633
VAR n1000 0.0008 0.0011 0.0009 0.0026 0.0025 0.0007 0.0010 0.0009
DR MSE n1000 0.0007 0.0008 0.0008 0.0012 0.0013 0.0007 0.0009 0.0009
BIAS n1000 -0.0003 -0.0001 0.0000 -0.0009 -0.0009 -0.0003 -0.0006 -0.0006
VAR n1000 0.0007 0.0008 0.0008 0.0012 0.0013 0.0007 0.0009 0.0009
DR.MIS MSE n1000 0.0021 0.0010 0.0008 0.0015 0.0013 0.0020 0.0026 0.0025
BIAS n1000 0.0352 0.0003 0.0001 -0.0002 -0.0004 0.0350 0.0398 0.0395
VAR n1000 0.0009 0.0010 0.0008 0.0015 0.0013 0.0008 0.0010 0.0009
STRAT MSE n1000 0.0216 0.0012 0.0010 0.0016 0.0014 0.0214 0.0271 0.0269
BIAS n1000 0.1441 0.0141 0.0141 0.0163 0.0159 0.1439 0.1619 0.1617
VAR n1000 0.0008 0.0010 0.0008 0.0013 0.0011 0.0007 0.0009 0.0008
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misspecified.  Here, we see that as long as the confounders, X1, are included, the bias in 
the estimator is negligible.  If, however, the confounders are not included, then the 
estimators have a larger degree of bias. 
Note that, compared to IPTW and STRAT methods, the DR.MIS bias is still 
relatively low.  This is due in part to the particular misspecification that was used.  One 
can imagine that as the outcome model departs further from the true model – say, by 
introducing unrelated variables, or in a more complex relationship, leaving off more 
covariates – the bias of  may become very significant.  Of course, this is entirely true 
outside of the paradigm of propensity score applications as well. 
As discussed in the Methods section, some literature points out that introducing 
X3 type variables in the propensity score model increases the variance of .  This is 
seen in Table 6 most prominently for the IPTW application method, by comparing Model 
3 against Model 5.  The variance of the estimator increases from 0.0009 to 0.0025.  The 
pattern of increasing variance holds true for the other propensity score methods as well.  
Here again, it should be noted that the particular conditions of our data generating 
process likely inherently limit the increase in variance that the introduction of X3 
variables may cause.  First, in our case there is only one X3 type variable; second, the 
distribution of that variable is standard normal.  If several X3 variables were introduced 
to the propensity score model, or if the X3 variables differed more substantially in 
location or scale, then it is likely that there would be a larger impact on the variance of 
. 
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Finally, just comparing IPTW and STRAT results in Table 6, the STRAT method 
consistently had the most bias, while the IPTW method consistently had the highest 
variance.  The two are effectively equivalent when evaluated on MSE. 
We turn now to assessing the standard errors of the  estimators from the 
simulation.  We used bootstrap sampling to estimate the standard errors and calculate the 
coverage rates of the resulting 95% confidence intervals under each of the propensity 
score application methods.  We confined our bootstrap sampling to only those propensity 
score models that contained the confounders X1, since the previous step demonstrated 
that including X1 type variables is necessary for achieving unbiased treatment effect 
estimates. 
Table 7 below summarizes the coverage rates for two types of confidence 
intervals, the 95% percentile interval and the 95% normal confidence interval.  We can 
see that, using the Percentile CI approach, under most propensity score model 
specifications, the actual coverage rate lags the nominal 95% rate by .5 to 3 percentage 
points.  The DR method has a very consistent actual coverage rate, regardless of 
propensity score model.  The IPTW method usually has the coverage rate closest to 
nominal, although it is usually pretty close to the others.  Meanwhile, in the lower panel, 
we can see the IPTW method consistently has a coverage rate within 1 percentage point 
of the nominal 95% rate.  Recall from Table 6 above that the IPTW estimator always has 
the highest variance under our simulation conditions.  Finally, the stratification method in 
general has the greatest departure from the nominal coverage rate. 
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Table 7.  95% confidence interval coverage rates. 
 
As one final demonstration from our simulation study, we return to the 
representative simulated dataset summarized in Table 3.  In that discussion we pointed 
out that the crude, unadjusted estimate of the risk difference was 0.318.  Estimating the 
propensity scores for that dataset and applying the IPTW and DR methods (using correct 
propensity score model specification and correct outcome model) results in adjusted 
treatment effect estimates of 0.168 and 0.167, respectively.  These adjusted estimates are 
well within two standard errors of the actual treatment effect for the simulation setup, 
which was approximately 0.2.  This reinforces that crude treatment effect estimates can 
be misleading; it is critical to adjust for confounders. 
  
Propensity Score Propensity Score Model
Application Method X1 X1X2 X1X3 X1X2X3
Percentile CI IPTW 0.934 0.944 0.935 0.929
DR 0.923 0.924 0.929 0.926
DR.MIS 0.945 0.935 0.932 0.927
STRAT 0.925 0.919 0.935 0.927
Normal CI IPTW 0.944 0.941 0.954 0.951
DR 0.939 0.938 0.939 0.942
DR.MIS 0.953 0.940 0.941 0.940
STRAT 0.923 0.926 0.932 0.929







4.1 Background and objectives. 
As cancer treatment strategies are improving, more patients are living longer after 
diagnosis and treatment (Geisberg and Sawyer, 2010).  While that is undoubtedly a 
positive outcome, a concern is whether the cancer treatment therapies increase the risk of 
cardiotoxicity in cancer survivors.  Cardiotoxicity is long term damage to the heart, and 
impaired heart function.  It manifests itself over a long period of time, as late as 20 years 
after initial exposure.  One particular cancer treatment that has been very effective in 
increasing the 5-year survival rate is a class of agents known as anthracyclines.  
Unfortunately, an estimated 5% to 23% of patients who undergo such cancer treatment 
later developing late-onset heart failure secondary to anthracycline-induced cardiotoxicity 
(Geisberg and Sawyer, 2010). 
The data for this study come from 95 breast cancer patients at Vanderbilt 
University.  The subjects had received one of two cancer treatment regimens, either 
anthracycline or herceptin, an alternative treatment type.  The fundamental research 
question of interest is whether there is a difference in the risk of cardiotoxicity depending 
on which type of cancer treatment was received.  In this study, the binary outcome of 
36  
cardiotoxicity is determined based upon measurement of the “ejection fraction” at 
multiple time points during the study.  The ejection fraction is a measurement of how 
much blood is pumped out of the heart with each beat.  Two conditions must hold for 
cardiotoxicity to be evaluated as occurring: 
1. The lowest measured ejection fraction must be less than 55. 
2. The lowest measured ejection fraction must be less than 90% of the baseline 
ejection fraction. 
A variety of demographic and biometric variables were recorded at baseline. The 
case study dataset contained the binary outcome variable, the binary treatment variable, 
and 19 covariates.  Of these, 10 were on the continuous scale, and 9 were categorical 
(mostly dichotomous).  The covariates on the continuous scale included demographic 
data, such as age, and biomedical baseline data, such as heart rate and blood pressure.  
The covariates on the categorical scale included mainly indicators related to previous 
health events, such as whether the subject had a history of hypertension, and current 
medications, such as whether the patient was on beta blockers at the time of the baseline 
assessment.  See Table A4 in the Appendix for a full description of all the covariates in 
the dataset. 
The goal of this study, then, is to determine whether the risk of cardiotoxicity 
differs between patients receiving the anthracycline treatment versus those receiving 
herceptin.  As an observational study, the patients were not randomly assigned to receive 
one of these treatments or the other.  No demographic or biomedical factors were 
specifically controlled for.  The desire, however, is to see if the data can tell us anything 
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about the relative cardiotoxicity risk for patients under the two different treatments, after 
controlling for these many other factors.  Given that this is observational data with high 
dimensionality, and the objective is to estimate a binary treatment effect, propensity score 
methodologies seem well suited for this case. 
4.2 Results. 
We had 10 continuous and 9 categorical covariates.  Tables 8 and 9 below 
summarize the distributions of those variables, including how they differ among 
treatment group (Table 8) and outcome (Table 9).  The columns labeled “p” indicate the 
p-value of a test for whether there is a statistically significant difference in the 
distributions between the two groups.  The columns labeled “test” indicate the type of 
statistical test that was performed.  For continuous variables, a one-way ANOVA 
(equivalent to a t-test, since there are only two groups) was performed if the distribution 
was approximately normal, otherwise the nonparametric Kruskal-Wallis Rank Sum Test 
was performed.  For categorical variables, a chi square test was performed unless the cell 
counts were too low, in which case a Fisher’s Exact Test was performed. 
In Table 8 below, we can see that the majority of the covariates are fairly well 
balanced at the outset relative to the treatment group (relatively high p-values, and low 





Table 8.  Baseline distribution of covariates by TREATMENT group. 
 
In Table 9 below, we are not concerned with balance of covariates between levels 
of the outcome variable.  However, we are interested in an initial assessment of 
association between the covariates and the outcome, because we will want to include any 
covariates that do have such an association in our outcome regression model.  However, 
Karnofsky Score is the covariate with the lowest p-value for this test of association, and 
its p-value is 0.164, not close to the traditional threshold of 0.05.  While this may be a 
result of a true lack of association with the outcome for all of these covariates, it may also 
be an artifact of the fairly low sample size involved, a total of 95 observations, with only 
TREATMENT
ac her p test SMD
n 67 28
CONTINUOUS 
VARIABLES Kar.Score (median [IQR]) 100.00 [90.00, 100.00]  90.00 [90.00, 100.00] 0.218 KW 0.212
Age (median [IQR])  49.00 [39.50, 58.00]  51.50 [45.75, 57.00] 0.443 KW 0.158
Ht.in (mean (sd))  64.32 (2.28)  64.26 (4.11) 0.928 ANOVA 0.018
Wt.lb (mean (sd)) 162.19 (33.09) 175.03 (43.77) 0.121 ANOVA 0.331
BMI (median [IQR])  26.90 [23.70, 30.00]  29.50 [23.15, 34.10] 0.200 KW 0.359
HR (mean (sd))  80.53 (12.99)  73.36 (10.48) 0.011 ANOVA 0.608
Sys.BP (mean (sd)) 123.67 (15.25) 123.79 (14.10) 0.972 ANOVA 0.008
Dias.BP (mean (sd))  76.39 (9.32)  75.29 (11.50) 0.624 ANOVA 0.106
Leisure.Indx (mean (sd))   1.04 (0.31)   1.09 (0.36) 0.435 ANOVA 0.171
Sport.Indx (median [IQR])   2.00 [0.67, 3.33]   2.01 [0.33, 3.08] 0.226 KW 0.240
CATEGORICAL 
VARIABLES Race = White (%)     59 (88.1)     26 (92.9) 0.743 Chi-Sq 0.164
Base.BC.Stage (%)         0.005 Chi-Sq 0.833
   Not staged      5 ( 7.5)      0 ( 0.0) 
   Stage I      8 (11.9)     12 (42.9) 
   Stage II     30 (44.8)     10 (35.7) 
   Stage III     24 (35.8)      6 (21.4) 
Hist.Hypertension = yes (%)     19 (28.4)     10 (35.7) 0.642 Chi-Sq 0.158
Hist.Hyperlipidemia = yes (%)     16 (23.9)      9 (32.1) 0.563 Chi-Sq 0.185
Hist.Arryhthmia.CSD = yes (%)      7 (10.4)      1 ( 3.6) 0.429 Exact 0.272
Hist.Diab.Mellitus = yes (%)      5 ( 7.5)      2 ( 7.1) 1.000 Exact 0.012
Fam.Hist.Dilatd.Card.Myop = yes (%)     20 (29.9)      3 (10.7) 0.065 Exact 0.490
Current.Beta.Block = yes (%)     10 (14.9)      3 (10.7) 0.749 Exact 0.126
Current.ACE.ARB = yes (%)      9 (13.4)      6 (21.4) 0.363 Exact 0.212
NOTES: SMD=Standardized Mean Difference.  KW=Kruskal-Wallis Rank Sum Test. ANOVA=One-way Analysis of Variance.
Chi-Sq=Chi-square test of independence. Exact=Fisher's Exact Test.
Continuous variables: Normally Distributed -- mean and standard deviation within treatment group are shown.
Non-normally distributed -- median and Inter-Quartile Range are shown.
Categorical variables: Frequency counts and percents within each treatment group are shown.
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18 in the positive outcome group.  Accordingly, in building our outcome regression 
model, we were fairly liberal in testing multiple variables for inclusion in the model. 
Table 9.  Baseline distribution of covariates by OUTCOME group. 
 
The crude estimate of treatment effect in terms of risk difference is -0.016, indicating 
almost no meaningful difference in risk of cardiotoxicity between the two treatment 
groups. 
As shown in Table 8 above, 9 out of 19 covariates were initially unbalanced 
(defined as having an SMD greater than 0.20) across the two treatment groups.  Our 
initial propensity score model entered all 19 covariates as main effects only into a logistic 
regression model with the treatment variable (chemotherapy type) as the outcome.  
OUTCOME
0 1 p test SMD
n 77 18
CONTINUOUS 
VARIABLES Kar.Score (median [IQR]) 100.00 [90.00, 100.00]  90.00 [90.00, 100.00] 0.164 KW 0.168
Age (median [IQR])  50.00 [42.00, 59.00]  47.50 [39.25, 55.25] 0.330 KW 0.186
Ht.in (mean (sd))  64.32 (2.91)  64.22 (3.02) 0.897 ANOVA 0.034
Wt.lb (mean (sd)) 164.92 (37.32) 170.47 (35.07) 0.568 ANOVA 0.153
BMI (median [IQR])  27.00 [23.00, 31.60]  28.60 [25.13, 31.30] 0.445 KW 0.168
HR (mean (sd))  78.12 (12.50)  79.67 (13.72) 0.645 ANOVA 0.118
Sys.BP (mean (sd)) 124.24 (15.38) 121.39 (12.40) 0.465 ANOVA 0.204
Dias.BP (mean (sd))  75.59 (10.22)  78.11 (8.74) 0.336 ANOVA 0.265
Leisure.Indx (mean (sd))   1.05 (0.33)   1.06 (0.29) 0.964 ANOVA 0.012
Sport.Indx (median [IQR])   2.00 [0.67, 3.33]   2.50 [0.75, 3.33] 0.633 KW 0.123
CATEGORICAL 
VARIABLES Race = White (%)     68 (88.3)     17 (94.4) 0.736 Chi-Sq 0.22
Base.BC.Stage (%)         0.273 Chi-Sq 0.574
   Not staged      5 ( 6.5)      0 ( 0.0) 
   Stage I     17 (22.1)      3 (16.7) 
   Stage II     29 (37.7)     11 (61.1) 
   Stage III     26 (33.8)      4 (22.2) 
Hist.Hypertension = yes (%)     24 (31.2)      5 (27.8) 1.000 Chi-Sq 0.074
Hist.Hyperlipidemia = yes (%)     21 (27.3)      4 (22.2) 0.888 Chi-Sq 0.117
Hist.Arryhthmia.CSD = yes (%)      7 ( 9.1)      1 ( 5.6) 1.000 Exact 0.136
Hist.Diab.Mellitus = yes (%)      5 ( 6.5)      2 (11.1) 0.614 Exact 0.164
Fam.Hist.Dilatd.Card.Myop = yes (%)     18 (23.4)      5 (27.8) 0.762 Exact 0.101
Current.Beta.Block = yes (%)     12 (15.6)      1 ( 5.6) 0.451 Exact 0.331
Current.ACE.ARB = yes (%)     11 (14.3)      4 (22.2) 0.474 Exact 0.207
NOTES: SMD=Standardized Mean Difference.  KW=Kruskal-Wallis Rank Sum Test. ANOVA=One-way Analysis of Variance.
Chi-Sq=Chi-square test of independence. Exact=Fisher's Exact Test.
Continuous variables: Normally Distributed -- mean and standard deviation within treatment group are shown.
Non-normally distributed -- median and Inter-Quartile Range are shown.
Categorical variables: Frequency counts and percents within each treatment group are shown.
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Checking the propensity score-adjusted balance by means of the SMD revealed that only 
four covariates remained unbalanced, and three of those had SMDs very close to the 0.20 
threshold.  The SMD for the fourth unbalanced covariate, Heart Rate, decreased 
substantially from 0.608 initially to 0.359 after adjustment by this specification of the 
propensity score.  This demonstrates how the adjustment by the propensity score 
generally improves the balance of the covariates that are included in the propensity score 
model. 
Nevertheless, in our simulation study above, we reaffirmed the theme in the 
literature that including X3 (and by extension X4) type variables in the propensity score 
model increases the variance of our ATE estimators.  Therefore, we would prefer to have 
a propensity score model specification that includes only X1 and X2 type variables.  We 
went through the list of 19 covariates and classified each as X1 (related to both treatment 
and outcome), X2 (related to outcome only), X3 (related to treatment only), or X4 
(related to neither).  It should be noted that we were fairly generous in our determination 
of whether a covariate was related to treatment or outcome because, as shown in Tables 8 
and 9, there are very few strong associations from any of the covariates.  We then revised 
the propensity score model to include only X1 and X2 type variables.  Table 10 below 
summarizes the SMD for each covariate before any adjustment and after adjustment 
under the two different propensity score models.  Shaded cells in the table indicate SMDs 




Table 10.  Standardized Mean Diffs before and after adjustment on propensity score. 
 
Model 2 constituted our final propensity score model, because all of the X1 and 
X2 type covariates are balanced, as assessed by the SMD.  Having settled on a propensity 
score model, we proceeded to estimate the ATE.  Given the results of our simulation 
study, we focused our efforts on the Doubly Robust propensity score application method.  
This entailed fitting a logistic regression model in which our binary outcome, 
cardiotoxicity, was regressed on the treatment variable, chemotherapy type, as well as all 
Covariate Propensity Score Model
Type 0 1 2
CONTINUOUS 
VARIABLES Kar.Score X1 0.212 0.044 0.036
Age X2 0.158 0.203 0.099
Ht.in X4 0.018 0.034 0.013
Wt.lb X3 0.331 0.054 0.366
BMI X3 0.359 0.042 0.356
HR X3 0.608 0.359 0.539
Sys.BP X2 0.008 0.102 0.005
Dias.BP X2 0.106 0.215 0.019
Leisure.Indx X4 0.171 0.091 0.376
Sport.Indx X4 0.24 0.052 0.233
CATEGORICAL 
VARIABLES Race X4 0.164 0.164 0.158
Base.BC.Stage X1 0.833
   Not staged
   Stage I 0.151 0.053
   Stage II 0.145 0.020
   Stage III 0.185 0.046
Hist.Hypertension X4 0.158 0.109 0.056
Hist.Hyperlipidemia X4 0.185 0.147 0.078
Hist.Arryhthmia.CSD X4 0.272 0.207 0.366
Hist.Diab.Mellitus X4 0.012 0.077 0.156
Fam.Hist.Dilatd.Card.Myop X3 0.49 0.125 0.433
Current.Beta.Block X2 0.126 0.199 0.174
Current.ACE.ARB X4 0.212 0.008 0.123
NOTES:  Shaded cells indicate SMDs greater than 0.20.
Bold font rows indicate covariates categorized as either type X1 or type X2.
PS Model 0 is unadjusted; Model 1 includes all 19 covariates as main effects only; Model 
2 includes only X1 and X2 type covariates.
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X1 and X2 type covariates, that is, all covariates related to outcome, whether or not also 
related to treatment.  Of course, this is the same set of covariates as those used in building 
our propensity score model. 
We used a stepwise selection procedure applied to the full set of X1 and X2 
covariates (the six covariates identified in bold font in Table 10) to find the logistic 
regression model with the best fit for estimating the outcome variable, while requiring 
that the treatment variable be included in the model.  It turned out that no covariates were 
selected into the model! Regardless of what subset of X1 and X2 variables was tried, no 
other covariates were deemed significant.  We therefore expanded our scope and tested 
all 19 covariates for inclusion in the outcome regression model along with the treatment 
variable.  Again, no covariates were selected into the model with the treatment variable. 
The one exception to the above depended on the form of specifying the covariate 
indicating the subject’s breast cancer stage.  If this was entered in the model as a 4-level 
factor variable, then it was not selected in the stepwise procedure.  If, however, it was 
entered as a series of three binary dummy variables, then “Stage2” was selected into the 
model.  In this regression model, Stage2 had a p-value of 0.077, and the treatment 
variable had a p-value of 0.981, with a point estimate of -0.014 (i.e., an estimated odds 
ratio of 0.986, so essentially no treatment effect).  Without the adjustment for “Stage2,” 
the model contained the treatment variable only.  In this case, the treatment variable had a 
p-value of 0.861, and a point estimate of -0.102 (odds ratio = 0.903). 
Under the Doubly Robust propensity score application method, the formula for 
the estimated risk difference is: 
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= 1 − ( − ̂ ) ( , )̂ −
1 (1 − ) − ( − ̂ ) ( , )
(1 − ̂ ) , 
Using this formula in the case where the outcome regression model includes only the 
treatment variable, we obtain an estimate of the treatment effect of = −0.0103. 
This compares to the crude estimate of -0.0155.  There really is not much difference 
between the crude and the adjusted estimates in this case, but of course, there are not any 
additional covariates strongly related to the outcome either that might have been 
confounding the treatment effect. 
The bootstrap standard error of our estimate is 0.098, and the 95% normal 
confidence interval of the ATE is (-0.198, 0.185).  The bootstrap ATE estimates do look 
normally distributed in a histogram, so this 95% CI seems appropriate (the percentile 
method for the confidence interval results in a very similar range).  In conclusion, we do 









Observations.  Our simulation exercise provided several insights into propensity 
score methodologies.  In some cases, features of these methodologies that have been 
highlighted in the literature were reproduced and confirmed; in other cases, we derived 
insights that affected our own choices regarding how to analyze our case study data.  The 
first observation from the simulation is that the sample size of the dataset can have a 
substantial impact on the variance of the estimators.  This is, of course, exactly what we 
know to expect from basic statistical theory.  Nevertheless, understanding the scale of the 
difference and how it varies across the different propensity score application methods 
was beneficial, particularly as our case study data had a low sample size as well 
(discussed more below).  In our simulation scenarios, the coefficient of variation 
(standard deviation divided by the mean) of our effect estimates ranged from 1.4 to 2.8 
for the low sample size datasets, and it ranged from 0.13 to 0.25 for our large sample size 
datasets. 
Second, our simulation illustrated the process of checking the balance of 
covariates after adjusting on the propensity score.  We focused on inspecting the 
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standardized mean differences, but other methods could be used as well.  We showed that 
adjusting for the propensity score can result in balancing the covariates across treatment 
groups. 
Our simulation also provided an illustration of the doubly robust property of the 
DR method.  Even when the propensity score model was misspecified, our ATE 
estimates were unbiased; this was because the outcome regression model was correctly 
specified.  In the DR.MIS method, which had a misspecified outcome regression model, 
moderate bias resulted if the propensity score model did not include all confounders.  In 
this simulation setup, negligible bias resulted under the DR.MIS method as long as X1 
variables were included in the propensity score model.  Nevertheless, it is likely that in 
more complex relationships, more substantial bias would result when both outcome 
model and propensity score model are misspecified and the departures of those 
misspecifications from the true underlying models becomes more severe. 
Next, the simulation analysis demonstrated that, under these conditions at least, 
the DR method is preferable to IPTW and Stratification.  Even if we assume a 
misspecified outcome model is settled upon, the MSE of the resulting effect estimates are 
lower than the MSEs under the alternative methods.  There is a bias-variance tradeoff; 
stratification improves on variance but is deficient on bias, while IPTW has the opposite 
effect.  Combining these different goals into the MSE measure leads us to prefer the DR 
method. 
Our simulation also illustrated the increase in variance of estimators if X3 type 
variables are included in the propensity score model.  However, in most of our scenarios 
that increase was very modest.  This supports the notion that the “cost” of including such 
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variables is low, and so to simplify analysis, or in cases where it is difficult to determine 
what the true relationships are, it may be reasonable to include these variables.  Of 
course, our simulation had only one specific X3 type variable, with a straightforward 
relationship to the treatment variable.  In real life, these relationships could be more 
complex, and the strength of the relationships can range from very low to very high. 
Our analysis of propensity score standard errors using bootstrap estimates 
generally leads to confidence intervals with empirical coverage rates from one-half to 
three percentage points less than the nominal 95% coverage rate.  The stratification 
method consistently had the lowest empirical coverage rate.  This makes sense given that 
it generally had the highest bias, yet was among the lowest on variance.  This finding is 
also consistent with the results of a simulation study by Austin, et al. (2010). 
Limitations.  In any simulation analysis, there are always more interesting 
questions that arise than can be covered within a reasonably defined scope.  In our case, 
and with respect to connecting our simulation with our case study, we have two 
categories of limitations that future work could examine.  First, the number and 
distributions of our covariates were both limited.  Not that we must mimic our case study 
dataset to derive relevant insights, but some questions may be more illuminated with a 
more complex simulation setup.  For example, it was stated above that the DR method is 
preferable to IPTW and stratification because, even assuming the misspecified DR 
model, the overall MSE was better.  However, if the outcome actually has a more 
complex relationship to the treatment and, say, to multiple other covariates (more than 
just the 4 in our setup), perhaps one of the other two methods would be preferred to the 
DR method.  After all, IPTW and stratification do not make further use of the covariates 
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after the estimation of the propensity scores.  If an outcome regression model is too far 
off the mark, it could be the case that the bias introduced would lead to one of the other 
two methods being preferable.  
Second, our setup included exactly one X3 type variable.  As explained above, 
some authors have highlighted that including X3 type variables in the propensity score 
model increases the variance of the estimators.  Other authors have suggested that the 
cost of including these variables is low, so an analyst should simply include all measured 
covariates from the outset.  Our setup did not provide a means to truly evaluate this issue, 
for example by doing sensitivity testing assuming various numbers and distributions of 
X3 variables, and different scenarios related to their inclusion or exclusion in the 
propensity score models.  It would interesting to determine if more instructive guidance 
could be determined on this subject. 
5.2 Case study. 
Observations.  The most poignant conclusion from our propensity score analysis 
of the case study data is that there is no evidence of a non-zero treatment effect, even 
after adjustment and balancing on covariates.  The difference between the crude 
treatment effect estimate and the propensity score-adjusted estimate is minimal, and both 
of these estimates are not statistically significantly different from zero.  Few variables 
had strong univariate associations with the treatment group, and none of the variables had 
a strong univariate association with the outcome. 
The propensity score balancing approach worked as expected for the most part.  
Some covariates, such as Heart Rate, remained unbalanced even after trying variations of 
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it in the propensity score model, such as a quadratic function, or an interaction with other 
variables.  In this case, it is useful to return to the idea of only including X1 and X2 type 
variables in the propensity score model.  Heart Rate was categorized as an X3 type 
variable: it is related to treatment (p = 0.011), but not to outcome (p = 0.645).  Therefore, 
we really need not include it in the propensity score model, and we do not need to insist 
on balance for that variable. 
Limitations. An important dynamic running throughout this case study analysis, 
however, is the very low sample size of the dataset.  There were only 95 observations, 
and only 18 observations having the outcome of cardiotoxicity.  Meanwhile, there were 
quite a large number of covariates – 19 included in the specific analysis here.  Nearly half 
of these are categorical variables, meaning that there is serious sparseness in the data.  
While this analysis does not reveal any associations, it could well be that collecting a 
larger dataset or monitoring the subjects for a longer period of time may help reveal 
actual effects that do exist.  Particularly as cardiotoxicity may be a condition that takes a 
fairly long amount of time to develop, or at least to manifest itself, the extended 
monitoring of subjects may be insightful. 
Another limitation of the case study analysis has to do with missing data within 
the set of covariates.  In the case study, the original dataset consisted of over 1200 
variables.  Many of these were redundant in some respects, and others were effectively 
summarized in other variables, such as “Sport Index” or “Leisure Index,” which both 
served as summaries of multiple responses from the CHAMPS questionnaire set of 
variables.  Nevertheless, much missing data existed in the dataset.  Of the over 1200 
variables, only about 20 had sufficient completion rates to be included in our analysis.  
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Within this subset, about half still had missing values, with the frequency of missing 
values ranging from 1 to 8 out of the 95 observations.  In this analysis, all missing values 
were simplistically assigned to be the mean or median or mode of their respective 
distributions, as seemed most appropriate given the particular variable.  A study focused 
solely on the most accurate estimation of the treatment effect would require more 
attention be given to this missing data issue.  Specifically, multiple imputation methods 
would be conducted for estimating the actual values of the missing data, based on other 
existing covariates, and sensitivity analyses would be conducted for estimating how much 
the missing data assumptions and models affect the final estimates of treatment effects.  
For our purposes, we are primarily interested in the question of propensity score 
methodologies, and in particular how best to model the propensity score and how best to 
apply estimated propensity scores; detailed missing data analysis is beyond our scope.  
Furthermore, with the estimated treatment effect being so close to zero, the low number 
of observations affected by the missing data, and the minimal apparent associations in the 
dataset as a whole, it is exceedingly unlikely that conclusions regarding the treatment 
effect would change. 
A final limitation of the case study data analysis is that there was in fact fairly low 
overlap in propensity scores between the treatment groups.  According to some authors 
(for example, Little and Rubin, 2000), this implies that there may be little comparability 
between the groups, and so we cannot actually draw causal inferences from the analysis.  
While this may be, it is apparent that there is not even associational inference to made 
with this dataset, let alone causal inference! 
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5.3 General comments on propensity score methodology. 
Propensity score methodologies are not a panacea.  Many challenges exist in 
correctly applying and drawing insights from them.  The specification of the propensity 
score model is not a trivial task.  The choice of propensity score application method is 
important and will lead to a set of follow-on decisions.  If the doubly robust method is 
chosen, then the specification of the outcome regression model is an important task.  If 
stratification is chosen, then ensuring overlap of propensity scores between the treatment 
groups and deciding where stratum boundaries should be will both require attention.  If 
IPTW method is chosen, although it is perhaps the simplest method to execute, then one 
must be aware of the potential for high weights (which may lead to the need for 
trimming) and, in general, realize that the variance of the estimators may be higher than 
under other methods. 
Nevertheless, the benefits of the propensity score approach are substantial.  
Reducing a high-dimensional dataset into a single scalar score can assist in figuring out 
how similar or disparate the dataset observations are.  Using this score for adjustment 
helps, in a straightforward way, to “level the playing field” with respect to the treatment 
groups.  Considering the difficulties and limitations of experimental data, the ability to 
derive causal inferences from observational data is extremely valuable.  There is no 
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6.1 Supplementary Tables 
Table A1. Summary of outcome vs treatment, representative simulated dataset. 
 
 
Table A2. Summary of outcome vs treatment, case study dataset. 
 
  
Y=0 Y=1 Ttl P(Y=1|Z=z)
Z=0 272 240 512 0.469
Z=1 104 384 488 0.787
Ttl 376 624 1000
Crude Risk Diff. 0.318
Y=0 Y=1 Ttl P(Y=1|Z=z)
Z=0=ac 54 13 67 0.194
Z=1=her 23 5 28 0.179
77 18 95
Crude Risk Diff. -0.015
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Table A3. MSE, Bias, and Variance for all four propensity score application 




                                                          
7 The “exception” mentioned in the text on page 29 in Section III refers to the fact that the reduction in 
MSE for the DR and DR.MIS methods is higher than the factor of 13, as mentioned for the IPTW method 
for models excluding X1. The reduction is actually by a factor of a little over 100, for DR, and around 47, 
for DR.MIS.  But this is consistent with the rest of the explanation in that part of the text.  Because DR 
method has virtually no bias, MSE is entirely driven by variance; any reduction in variance, therefore, 
translates to a virtually identical reduction in MSE.  DR.MIS, meanwhile, has some bias, but much less 
than the IPTW or STRAT methods.  Therefore, the reduction in variance is ameliorated to some extent 
when viewing the reduction in MSE, but it is not ameliorated to the degree that it is for the IPTW and 
STRAT methods.  In those methods, the reduction in MSE was by a factor of around 13, despite a 
reduction in variance by a factor of over 300.  For DR.MIS, the reduction in variance by a factor of a little 
over 100 resulted in a reduction of MSE by a factor of about 47.  
Propensity Score Model
Int. only Confounders Included No Confounders
NULL X1 X1X2 X1X3 X1X2X3 X2 X3 X2X3
IPTW MSE n100 0.2829 0.1237 0.1192 0.2810 0.3069 0.2746 0.3564 0.3593
n1000 0.0216 0.0011 0.0009 0.0026 0.0025 0.0214 0.0278 0.0276
BIAS n100 0.1409 -0.0004 0.0001 -0.0017 0.0004 0.1416 0.1573 0.1604
n1000 0.1441 0.0011 0.0009 0.0008 0.0005 0.1438 0.1637 0.1633
VAR n100 0.2630 0.1237 0.1192 0.2810 0.3069 0.2546 0.3316 0.3336
n1000 0.0008 0.0011 0.0009 0.0026 0.0025 0.0007 0.0010 0.0009
DR MSE n100 0.0806 0.0870 0.0882 0.1399 0.1715 0.0807 0.0948 0.0965
n1000 0.0007 0.0008 0.0008 0.0012 0.0013 0.0007 0.0009 0.0009
BIAS n100 -0.0003 -0.0010 -0.0015 -0.0032 -0.0031 -0.0003 -0.0015 -0.0011
n1000 -0.0003 -0.0001 0.0000 -0.0009 -0.0009 -0.0003 -0.0006 -0.0006
VAR n100 0.0806 0.0870 0.0882 0.1399 0.1715 0.0807 0.0948 0.0965
n1000 0.0007 0.0008 0.0008 0.0012 0.0013 0.0007 0.0009 0.0009
DR.MIS MSE n100 0.1022 0.1026 0.0903 0.1673 0.1830 0.0930 0.1221 0.1138
n1000 0.0021 0.0010 0.0008 0.0015 0.0013 0.0020 0.0026 0.0025
BIAS n100 0.0338 -0.0005 -0.0017 -0.0034 -0.0040 0.0341 0.0364 0.0379
n1000 0.0352 0.0003 0.0001 -0.0002 -0.0004 0.0350 0.0398 0.0395
VAR n100 0.1010 0.1026 0.0903 0.1673 0.1830 0.0918 0.1208 0.1124
n1000 0.0009 0.0010 0.0008 0.0015 0.0013 0.0008 0.0010 0.0009
STRAT MSE n100 0.2868 0.1131 0.0991 0.1420 0.1221 0.2830 0.3452 0.3487
n1000 0.0216 0.0012 0.0010 0.0016 0.0014 0.0214 0.0271 0.0269
BIAS n100 0.1407 0.0115 0.0127 0.0120 0.0127 0.1425 0.1555 0.1599
n1000 0.1441 0.0141 0.0141 0.0163 0.0159 0.1439 0.1619 0.1617
VAR n100 0.2670 0.1130 0.0989 0.1418 0.1219 0.2627 0.3211 0.3231




Table A4. Description of case study variables. 
 
 
6.2 Background and Context: Logical Inference from Scientific Research. 
Philosophy of knowledge and theories of causation.  Why do we engage in 
scientific research?  Quite simply, to gain knowledge about our world.  Rarely, however, 
is knowledge sought as nothing more than a snapshot of current conditions; rather, we 
want to understand how conditions change over time and, in particular what causes those 
changes, and how causes and effects relate to each other.  We want to know how things 
work.  It is probably only a slight oversimplification to say that scientific research is, 
fundamentally, intended to identify and describe “cause-and-effect” relationships in our 
world. 
CONTINUOUS 
VARIABLES Kar.Score Karnofsky Score*
Age Age at baseline
Ht.in Height in inches
Wt.lb Weight in pounds
BMI Body Mass Index
HR Heart rate
Sys.BP Systolic blood pressure
Dias.BP Diastolic blood pressure
Leisure.Indx
Leisure index, a composite score summarizing several answers from 
the CHAMPS physical activity questionnaire
Sport.Indx
Sport index, a composite score summarizing several answers from 
the CHAMPS physical activity questionnaire
CATEGORICAL 
VARIABLES Race Subject's race, either White or Non-white
Base.BC.Stage Baseline breast cancer stage
   Not staged
   Stage I
   Stage II
   Stage III
Hist.Hypertension History of hypertension
Hist.Hyperlipidemia History of hyperlipidemia
Hist.Arryhthmia.CSD History of arrhythmia or conduction system disease
Hist.Diab.Mellitus History of diabetes mellitus
Fam.Hist.Dilatd.Card.Myop Family history of dilated cardiomyopathy
Current.Beta.Block Currently on beta blocker
Current.ACE.ARB Currently on ACE inhibitor
* A measure assessing functional impairment, ranging from 0% (dead) to 100% (no complaints/no evidence of disease)
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Knowledge as justified true belief.  There is a long and rich history in both 
philosophy and science (and the philosophy of science!) of exploring exactly what is 
meant by knowledge, and causation, and inference.  One traditional theory of knowledge 
is the “JTB” theory of knowledge:  we have real knowledge about something when we 
have a Justified, True Belief about that thing.  It would not make sense to say we knew 
something if we did not believe it.  If we believed something, but our belief was false, it 
certainly does not seem like we should say that we know it.  Finally, if we have a belief, 
and the belief is true, but we are not justified in holding our belief (we are right about the 
belief only due to “luck,” say), then again, it does not seem like we should claim to have 
knowledge.  An example for this latter condition might be the following situation: you 
come home from work in the evening and see that the grass is wet, therefore you develop 
a belief that it rained earlier in the day.  Perhaps it did in fact rain in the morning, so your 
belief happens to be true; but the grass dried after the rain, and it is now wet again 
actually because your neighbor watered his lawn in the afternoon.  In this case, if the only 
justification for your belief about it raining earlier is the currently wet grass, then we 
would say that you do not have knowledge; your belief is true only from luck, and you 
are not justified in holding that belief8. 
Even though the JTB theory of knowledge does have its limitations and 
deficiencies, for our purposes, it is a sensible and pragmatic theory and provides a solid 
                                                          
8 Certainly, there could be additional evidence leading to your belief that it rained.  Perhaps the sky is very 
overcast.  Perhaps not just the grass, but the sidewalk, and street, and cars are all wet too.  Perhaps you 
actually saw it raining.  It is the full body of evidence available, along with the set of alternative 
explanations for that full body of evidence, that would determine whether a particular belief is justified 
sufficiently to count as “knowledge.” 
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basis for proceeding to ideas related to causal inference9.  “Causal inference” is the 
process by which we use evidence to draw conclusions related to cause-and-effect 
relationships.  This subject, too, has a rich history, spanning fields of philosophy and 
every branch of science, including in particular, the social sciences, biological sciences, 
and economics.  Statistics, as a branch of science fundamentally concerned with deriving 
accurate and justified conclusions from empirical data, runs throughout all other sciences 
and is organically bound with philosophical ideas about logical inference.  We will 
explore one particular line of causal theories, because it constitutes the foundation of 
logical reasoning underlying much – perhaps even all – scientific research. 
Briefly, however, we distinguish two primary types of logical reasoning.  
Deductive reasoning takes premises and valid rules as implying, with certainty, particular 
conclusions.  For example:  In the morning, the sun is always in the East.  It is now 
morning; therefore, the sun is in the East.  If the premises are all true, then the conclusion 
must be true.  This approach has been roughly characterized as reasoning “from the 
general to the specific.”  Inductive reasoning takes premises and evidence and infers 
conclusions.  This is reasoning “from the specific to the general.”  Importantly, even 
under sound inductive reasoning, possibilities exist for alternative explanations than those 
inferred; standing theories are strong insofar as they are coherent with existing empirical 
data and support predictions about future empirical data, but they may be refined, 
qualified, and even at times, rendered inaccurate as our true knowledge of the world gets 
updated and expands. 
                                                          
9 A good place to start for exploring more about the benefits and drawbacks of the JTB theory of 
knowledge, and about subsequent theories of knowledge, is the Stanford Encyclopedia of Philosophy 
Ichikawa, J. J. and M. Steup (2014). The Analysis of Knowledge. The Stanford Encyclopedia of 
Philosophy. E. N. Zalta. URL = http://plato.stanford.edu/archives/spr2014/entries/knowledge-analysis/..   
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Irrefutable certainty then, in a strictly logical sense, is not the outcome of the 
inferential  process, or of inductive reasoning.  Consequently, irrefutable certainty is not 
the result of the scientific process, either, since that process relies in large part on 
inductive reasoning.  (Indeed, this is why it is sometimes claimed that scientific theories 
are never fully proven.)  Nevertheless, we certainly can and do have real knowledge 
about our world, if we can live with the traditional idea of knowledge as justified, true 
belief.  But the degree to which our beliefs constitute true knowledge is highly tied to 
how true those beliefs are, and how justified those beliefs are. 
Causal theories and counterfactuals.  Realizing then that many of our beliefs 
stemming from scientific research are beliefs about causes and effects, in order to think 
about how we can assess the truth status and the justification status for our cause-and-
effect beliefs, we now explore certain theories of causation.  The particular line of causal 
theories (i.e., what it means to say something is a cause, and how to establish cause-and-
effect relationships) we will focus on begins with David Hume in his Enquiry 
Concerning Human Understanding in 1748.  In Section VII of that treatise, Hume writes: 
“[W]e may define a cause to be an object followed by another, and where all the 
objects, similar to the first, are followed by objects similar to the second. Or, in 
other words, where, if the first object had not been, the second never had existed.” 
(Italics in original.) 
This is important because it is, apparently, the first time that causation is mentioned in a 
way that would later become known as “counterfactuals” (Menzies 2014).  
Counterfactuals are statements that invert statements about current or past conditions.  
For example, let us suppose that it rained this morning, so we may reasonably say 
something like, “It rained this morning, so the grass got wet.”  A counterfactual would 
invert the antecedent condition, and this counterfactual is then typically followed by 
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some different (often opposite) effect.  Thus: “If it had not rained this morning, the grass 
would not have gotten wet.”  The difference between the true condition and its 
counterfactual, together with the difference between the actual outcome and the 
hypothesized outcome under the counterfactual condition, lead us to make inferences 
about causes and effects.  In the example, our inference is that the rain caused the grass to 
get wet10. 
As will be seen below, the idea of, and reliance on, counterfactual reasoning is 
absolutely central to our inferential process regarding causes and effects within the set of 
propensity score methodologies (indeed, it underlies most scientific research, as well as 
common inferences we make in our everyday lives).  Interestingly, as pointed out by 
Menzies, these two sentences by Hume actually presuppose rather different (though not 
incompatible) theories of causation.  Implicit in the first sentence is a “regularity” theory 
of causation, what Hume refers to as “constant conjunction.”  With a regularity theory of 
causation, particular causes are always followed by their effects (Hitchcock 2012).  
Indeed, in subsequent exposition of his definition of causation, Hume emphasizes the 
requirement of “constant conjunction.”11  On the other hand, Hume’s second sentence in 
the quote above deals in hypotheticals, by reversing or contradicting an existing 
condition.  Although Menzies claims that this sentence by Hume is the “first explicit 
definition of causation in terms of counterfactuals,” Hume does not proceed to explore or 
                                                          
10 Note that we are not concerned here currently with evaluating the truth status of the claim, “If it had not 
rained this morning, the grass would not have gotten wet.”  Such evaluation is important for establishing 
the justification for our inference, but at this point, we are simply defining terms and demonstrating the 
process of counterfactual reasoning. 
11 Two other criteria for causation besides constant conjunction, according to Hume, are spatial/temporal 
contiguity, and temporal succession Hume, D. (1748). An Enquiry Concerning Human Understanding.. 
These latter two criteria remain important even under a counterfactual theory of causation, which will be 
the foundation for the logical inference employed in this paper. 
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develop any counterfactual theory of causation.  Perhaps he viewed this sentence merely 
as amplifying the previous sentence, and did not in fact realize that later thinking would 
distinguish a truly separate condition, the truth status of which must be evaluated and 
analyzed for its implications related to causality.  At any rate, Holland (1986) seems to 
agree that Hume is the first philosopher whose analysis of causation is strongly relevant 
to our “potential outcomes framework” and “Rubin’s Causal Model,” both concepts 
which will be defined and discussed in more depth shortly. 
It was some time before other philosophers gave serious attention to 
counterfactuals, although John Stuart Mill did attempt to analyze the truth relationships 
among such statements (Menzies 2014).  The first use of the actual term “counterfactual” 
was apparently by Nelson Goodman in 1947 (Wikipedia).  However, Goodman’s focus in 
that paper was primarily on determining what other statements needed to hold, and what 
relationships among the statements needed to exist, in order to ascertain the truth status of 
a counterfactual claim (Goodman 1947); thus, his subject was much more in the line of 
Mill’s.  David Lewis, by contrast, formulated the “best known and most thoroughly 
elaborated counterfactual theory of causation” (Menzies 2014).  His (1973) paper 
presented his original theory, but he eventually made substantial revisions (2000) to 
address certain deficiencies that were revealed over the several decades following his 
initial paper.  His theory encompasses both deterministic causation, in which causes are 
followed by their effects with certainty, and “chancy causation,” in which the absence of 
the causal event c would have decreased the chance of the subsequent event e occurring. 
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6.3 Glossary and Acronyms 
ATE – Average Treatment Effect – the estimated or actual treatment effect assuming the 
treatment is administered to the entire population as compared to if the treatment is 
withheld from the entire population 
ATT – Average Treatment effect among Treated – the estimated or actual treatment 
effect for the subpopulation of units that actually receives (or were to receive) the 
treatment.  This differs from ATE if it is the case that those individuals in the population 
who actually receive (or would receive) the treatment have a smaller or larger treatment 
effect than those individuals who do not (or would not) receive the treatment. 
DR – Doubly Robust – a propensity score application method combining propensity 
score weights with an outcome regression model 
IPTW – Inverse Probability of Treatment Weighting – a propensity score application 
method that weights treatment observations by the inverse of the propensity score, and  
weights control observations by the inverse of (1 – propensity score) 
JTB – Justified True Belief – a traditional theory of knowledge within epistemology 
PS – Propensity Scores 
RCT – Randomized Controlled Trial 
SITA – Strongly Ignorable Treatment Assignment – the assumption within propensity 
score methodologies that, conditional on covariates, a unit’s response is independent of 
treatment assignment 
SMD – Standardized Mean Difference – A measure used to assess the balance of a 
covariate between the treatment and control group 
SUTVA – Stable Unit Treatment Value – the assumption within propensity score 
methodologies that a unit’s treatment effect is independent of all other units’ treatment 
assignments 
X1 – Confounders, the category of covariates related to both treatment and outcome 
X2 – The category of covariates related to outcome only, also called prognosticators 
X3 – The category of covariates related to treatment only 
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